# Retrospective analysis of the efficacy of total glycosides of paeony capsules combined with hydroxychloroquine in patients with primary Sjogren’s syndrome

## TL;DR

This study found that combining TGP capsules with HCQ improved symptoms and reduced inflammation in patients with primary Sjogren’s syndrome more effectively than HCQ alone.

## Contribution

The study demonstrates the enhanced efficacy of combining TGP with HCQ in treating primary Sjogren’s syndrome.

## Key findings

- The observation group showed a higher treatment efficacy (93.65%) compared to the control group (81.67%).
- Blood indicators and inflammatory markers improved significantly in the observation group.
- Disease evaluation scores decreased significantly in the observation group with no significant adverse reactions.

## Abstract

In this retrospective analysis, total glucosides of paeony (TGP) were compared with hydroxychloroquine (HCQ) in the treatment of patients with primary Sjogren’s syndrome (pSS).

In this retrospectively analysis, 157 patients with SS treated at the First Affiliated Hospital of Zhejiang University School of Medicine hospital between January 2020 and December 2023 were included. The analysis included the flow rates of saliva and tears before and after treatment in the control group and observation group, as well as levels of white blood cells (WB), hemoglobin (Hb), platelets (PLT), and immunoinflammatory indicators including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and serum immunoglobulin G (IgG) levels, disease evaluation scores and occurrence of adverse reactions.

Clinical baseline data were not statistically significant after six months of treatment between the two groups (P>0.05). In the observation group, the efficacy of treatment was 93.65%, whereas in the control group, it was 81.67% (P<0.05). Blood routine indicators (WB, Hb, PLT) significantly increased in the observation group (P<0.05). A significant decrease in immunoinflammatory markers (ESR, CRP, IgG) was observed in the observation group, compared with the control group (P<0.05). Disease evaluation scores scores in the observation groups significantly decreased (P<0.05). Adverse reactions showed no statistically significant (P>0.05).

In the treatment of pSS, TGP capsules and HCQ are combined to improve salivary and lacrimal gland function, suppress the release of inflammatory factors, repair damage to the blood system, control disease activity, show significant clinical efficacy, and have few adverse reactions.